Anti-Diabetic Medications: A promising therapeutic approaches for the Management of NAFLD | ||
| Records of Pharmaceutical and Biomedical Sciences | ||
| Article 8, Volume 5, Pharmacology-Pharmaceutics, January 2021, Pages 65-70 PDF (572.1 K) | ||
| Document Type: Mini-reviews | ||
| DOI: 10.21608/rpbs.2021.79353.1103 | ||
| Authors | ||
| ahmed ibrahim* 1; Reem mohamed Hazem2; Dina Abdelkarim Ali3; Yasser mohamed Moustafa4 | ||
| 1Department of Pharmacology & Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt | ||
| 2Department of Pharmacology &Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt. | ||
| 3Department of clinical Pharmacology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt | ||
| 4Pharmacology and Toxicology Department, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt. | ||
| Abstract | ||
| Type 2 diabetes and Nonalcoholic fatty liver disease are two of the most common metabolic diseases in the world, with an increasing prevalence. Patients with T2DM have a two-fold increased risk of developing NAFLD, The evidence that certain antidiabetic drugs boost NAFLD/NASH in T2DM patients is growing. However, there are no specific pharmacologic treatments available. This review aims to outline the data supporting the effectiveness of anti-diabetic drugs in the treatment of NAFLD, besides providing an overview of novel anti-diabetic therapies that have been proposed to achieve this goal. Most of these anti-diabetic agents demonstrate short-term efficacy, but have shown little to no impact on hepatic histology. Only thiazolides and GLP-1 receptor agonists have shown considerable improvement in hepatic histology. | ||
| Keywords | ||
| GLP-1; Steatohepatitis; Diabetes; NAFLD | ||
|
Statistics Article View: 478 PDF Download: 355 |
||
